<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05619692</url>
  </required_header>
  <id_info>
    <org_study_id>718-CNA-202</org_study_id>
    <nct_id>NCT05619692</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sage Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sage Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive&#xD;
      performance in participants with Alzheimer's Disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 27, 2022</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in the Wechsler Adult Intelligence Scale Fourth Edition-IV (WAIS-IV) Coding Test</measure>
    <time_frame>Baseline to Day 84</time_frame>
    <description>The WAIS-IV Coding Test is a valid and sensitive measure of cognitive dysfunction. Administration of the WAIS-IV Coding Test will use the traditional paper-and-pen format, in which the participant is required to identify the symbols matched to numbers using a key and write in the symbol beneath the associated number. The score will be based on the total number of codes correctly completed over a 120-second time limit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With At least One or More Treatment-emergent Adverse Events (TEAEs) and by Severity</measure>
    <time_frame>From the inform consent signing up to end of the study (Up to approximately Day 116)</time_frame>
    <description>An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. A TEAE is defined as an AE with onset after the start of IP, or any worsening of a pre-existing medical condition/AE with onset after the start of IP and throughout the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Withdraw Due to Adverse Events (AEs)</measure>
    <time_frame>From the inform consent signing up to end of the study (Up to approximately Day 116)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Mild Dementia</condition>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>SAGE-718</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1.2mg of SAGE-718 orally once daily for the first 6 weeks Days 1 to 42 [±2 days]), followed by 0.9 mg of SAGE-718 for the remainder of the Treatment period up to Day 84.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo-matching capsule once daily orally throughout the treatment period for up to Day 84.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAGE-718</intervention_name>
    <description>Softgel lipid capsules.</description>
    <arm_group_label>SAGE-718</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAGE-718-matching Placebo</intervention_name>
    <description>Softgel lipid capsules.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Meet the following criteria for mild cognitive impairment (MCI) or mild dementia due&#xD;
             to Alzheimer's Disease (AD) at Screening:&#xD;
&#xD;
               1. A memory complaint reported by the participant or their study partner&#xD;
&#xD;
               2. A Clinical Dementia Rating (CDR) score of 0.5 to 1.0 (inclusive) with a memory&#xD;
                  box score ≥0.5&#xD;
&#xD;
               3. Essentially preserved activities of daily living, in the opinion of the&#xD;
                  investigator&#xD;
&#xD;
               4. Brain Magnetic Resonance Imaging (MRI) report, obtained within the 2 years&#xD;
                  preceding the Baseline Period, that is consistent with the diagnosis of AD with&#xD;
                  no clinically significant findings of non-AD pathology that could account for the&#xD;
                  observed cognitive impairment&#xD;
&#xD;
          2. Have a score of 15 to 25 (inclusive) on the Montreal Cognitive Assessment (MoCA) at&#xD;
             Screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have participated in a previous clinical study of SAGE-718, have participated in a&#xD;
             previous gene therapy study, or have received study treatment in any other drug,&#xD;
             biologic, or device trial within 30 days or 5 half-lives (whichever is longer), unless&#xD;
             the participant participated solely in the placebo arm of the study. Additionally,&#xD;
             participants who have received treatment with antisense oligonucleotides (ASO) will be&#xD;
             excluded&#xD;
&#xD;
          2. Have a condition that precludes undergoing an MRI, in accordance with standard&#xD;
             operating procedures at the imaging facility (eg, ferromagnetic metal in the body,&#xD;
             claustrophobia), in a participant requiring MRI during Screening&#xD;
&#xD;
          3. Have any medical or neurological condition (other than AD) that might be contributing&#xD;
             to the participant's cognitive impairment or history of cognitive decline&#xD;
&#xD;
          4. Have a history, presence, and/or current evidence of&#xD;
&#xD;
               1. Brain surgery, deep brain stimulation, or any history of hospitalization due to a&#xD;
                  brain injury&#xD;
&#xD;
               2. Possible or probable cerebral amyloid angiopathy, according to the Boston&#xD;
                  Criteria&#xD;
&#xD;
               3. Treatment with an anti-amyloid therapy (including biologics) without subsequent&#xD;
                  MRI demonstrating the absence of amyloid-related imaging abnormalities&#xD;
&#xD;
               4. Seizures or epilepsy, with the exception of childhood febrile seizures&#xD;
&#xD;
          5. Be at risk for suicidal ideation as per Columbia-Suicide Severity Rating Scale&#xD;
             (C-SSRS) and/or in the opinion of the investigator&#xD;
&#xD;
          6. Have any of the following medical conditions:&#xD;
&#xD;
               1. Any clinically significant finding on 12-lead electrocardiogram (ECG) during&#xD;
                  Screening in the opinion of the investigator&#xD;
&#xD;
               2. Supine vital signs outside of the following ranges during Screening (vital sign&#xD;
                  measurements may be repeated once if initial values exceed these ranges):&#xD;
&#xD;
             i. Heart rate &lt;50 or &gt;100 bpm ii. Systolic blood pressure &lt;100 or &gt;160 mmHg iii.&#xD;
             Diastolic blood pressure &lt;60 or &gt;100 mmHg&#xD;
&#xD;
          7. Have a history, presence, and/or current evidence of serologic positive results for&#xD;
             human immunodeficiency virus (HIV)-1 or HIV-2, or hepatitis B or C&#xD;
&#xD;
          8. Have a positive pregnancy test, or be lactating, or intend to breastfeed during the&#xD;
             study&#xD;
&#xD;
          9. Is known to be allergic to any of SAGE-718 excipients, including soy lecithin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tiffany Lago, MD</last_name>
    <phone>617-733-6386</phone>
    <email>tiffany.lago@sagerx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sage Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrialsinquiry@sagerx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sage Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrialsinquiry@sagerx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sage Investigational Site</name>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrialsinquiry@sagerx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sage Investigational Site</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrialsinquiry@sagerx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sage Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrialsinquiry@sagerx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sage Investigational Site</name>
      <address>
        <city>Palm Beach Gardens</city>
        <state>Florida</state>
        <zip>33410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrialsinquiry@sagerx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sage Investigational Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrialsinquiry@sagerx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sage Investigational Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrialsinquiry@sagerx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sage Investigational Site</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrialsinquiry@sagerx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sage Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrialsinquiry@sagerx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sage Investigational Site</name>
      <address>
        <city>Papillion</city>
        <state>Nebraska</state>
        <zip>68046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrialsinquiry@sagerx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sage Investigational Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrialsinquiry@sagerx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sage Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrialsinquiry@sagerx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sage Investigational Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrialsinquiry@sagerx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sage Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrialsinquiry@sagerx.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>November 9, 2022</study_first_submitted>
  <study_first_submitted_qc>November 9, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2022</study_first_posted>
  <last_update_submitted>March 27, 2023</last_update_submitted>
  <last_update_submitted_qc>March 27, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SAGE-718</keyword>
  <keyword>Cognitive dysfunction</keyword>
  <keyword>NMDA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data sharing will be consistent with the results submission policy of ClinicalTrials.gov.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

